Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr;84(4):579-613.
doi: 10.1016/j.jinf.2022.01.002. Epub 2022 Jan 10.

Cross reactivity of spike glycoprotein induced antibody against Delta and Omicron variants before and after third SARS-CoV-2 vaccine dose in healthy and immunocompromised individuals

Sian Faustini  1 , Adrian Shields  2 , Gemma Banham  3 , Nadezhda Wall  4 , Saly Al-Taei  5 , Chloe Tanner  6 , Zahra Ahmed  7 , Elena Efstathiou  8 , Neal Townsend  9 , Margaret Goodall  10 , Tim Plant  11 , Marisol Perez-Toledo  12 , Aleksandra Jasiulewicz  13 , Ruth Price  14 , James McLaughlin  15 , John Farnan  16 , Julie Moore  17 , Louise Robertson  18 , Andrew Nesbit  19 , Grace Curry  20 , Amy Black  21 , Adam Cunningham  22 , Lorraine Harper  23 , Tara Moore  24 , Mark Drayson  25 , Alex Richter  26
Affiliations

Cross reactivity of spike glycoprotein induced antibody against Delta and Omicron variants before and after third SARS-CoV-2 vaccine dose in healthy and immunocompromised individuals

Sian Faustini et al. J Infect. 2022 Apr.
No abstract available

Keywords: COVID-19; Chronic kidney disease; Cross reactivity; Delta; Haemodialysis; Omicron; SARS-CoV-2; Variants of Concern; antibody response; vaccination.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Percentage of cohort with antibodies against Wuhan, Delta and Omicron strain. A-Detection of anti- Wuhan spike IgG in pre-2019 controls, a dialysis population, a cohort of health care workers who have had three PFZ vaccines and a Clinically Extremely Vulnerable population in general practice who have had two AZ and one PFZ vaccine. Results are given for pre and post 3rd dose of vaccination. Percentage of cohort that are considered seropositive are included above the dot plots. The red line represents the median of the seropositive individuals in that cohort. B-Detection of anti-Delta spike IgG for the same populations. C-Detection of anti- Omicron spike IgG for the same populations Pre- pre-3rd dose of vaccine and 6 months post 2nd dose. Post- 28 days post 3rd dose of vaccine. PPP- 3 Pfizer-BioNtech vaccines given in this cohort. AAP- two AstraZeneca ChAdOx1 nCoV-19 vaccines and the one Pfizer-BioNtech vaccine given in this cohort. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
See this image and copyright information in PMC

References

    1. Voysey M., Clemens S.A.C., Madhi S.A., Weckx L.Y., Folegatti P.M., Aley P.K. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99–111. Jan. - PMC - PubMed
    1. Polack F.P., Thomas S.J., Kitchin N., Absalon J., Gurtman A., Lockhart S. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603–2615. Dec. - PMC - PubMed
    1. England P.H. SARS-CoV-2 variants of concern and variants under investigation in England. Sage. 2021;(April).
    1. Cook A.M., Faustini S.E., Williams L.J., Cunningham A.F., Drayson M.T., Shields A.M. Validation of a combined ELISA to detect IgG, IgA and IgM antibody responses to SARS-CoV-2 in mild or moderate non-hospitalised patients. J Immunol Methods. 2021:494. Jul 1. - PMC - PubMed
    1. Faustini S.E., Jossi S.E., Perez-Toledo M., Shields A.M., Allen J.D., Watanabe Y. Development of a high-sensitivity ELISA detecting IgG, IgA and IgM antibodies to the SARS-CoV-2 spike glycoprotein in serum and saliva. Immunology. 2021;164(1):135–147. Sep 1. - PMC - PubMed

Publication types

Supplementary concepts